Comparison of Clinical Data Between Groups With and Without Cardiac Events
| Parameter | Cardiac events group (n = 89) | Non–cardiac events group (n = 379) | P |
| Age (y) | 64.4 ± 12.5 | 61.5 ± 14.4 | NS |
| Sex (male/female) | 68/21 | 272/107 | NS |
| NYHA class (I/II/III/IV) | 27/24/25/13 | 210/107/54/8 | <0.001 |
| Systolic blood pressure (mm Hg) | 117.0 ± 27.6 | 122.7 ± 22.2 | NS |
| Diastolic blood pressure (mm Hg) | 69.5 ± 12.4 | 72.6 ± 12.7 | NS |
| Heart rate (beats/min) | 74.4 ± 16.2 | 75.5 ± 18.9 | NS |
| Diabetes mellitus | 27 (30.3%) | 73 (19.3%) | NS |
| Hypertension | 24 (26.9%) | 92 (24.3%) | NS |
| Dyslipidemia | 10 (11.2%) | 94 (24.8%) | <0.001 |
| Atrial fibrillation | 19 (21.3%) | 90 (23.7%) | NS |
| Ventricular tachycardia/ventricular fibrillation | 34 (38.2%) | 117 (30.8%) | 0.262 |
| Underlying heart diseases | |||
| Ischemic heart diseases | 29 (32.5%) | 99 (26.1%) | NS |
| Nonischemic heart diseases | 60 (67.4%) | 280 (73.9%) | 0.2247 |
| History of prior myocardial infarction | 11 (12.3%) | 46 (12.1%) | NS |
| Diuretics | 74 (83.0%) | 247 (65.1%) | 0.001 |
| Angiotensin-converting enzyme inhibitors | 21 (23.5%) | 120 (31.6%) | NS |
| Angiotensin-receptor blockers | 29 (32.6%) | 140 (36.9%) | NS |
| Calcium channel blockers | 18 (20.2%) | 80 (21.1%) | NS |
| β-blockers | 51 (57.3%) | 256 (67.5%) | NS |
| Nitrates | 36 (40.4%) | 68 (17.9%) | <0.001 |
| Nicorandil | 8 (8.9%) | 48 (12.6%) | NS |
| Statins | 12 (13.4%) | 107 (28.2%) | 0.036 |
| Antiarrhythmic drugs | 38 (42.6%) | 171 (45.1%) | NS |
| Antiplatelet agent | 57 (64.0%) | 248 (65.4%) | NS |
| Anticoagulation agent | 38 (42.7%) | 157 (41.4%) | NS |
| BNP concentration (pg/mL) | 548.7 ± 659.1 (n = 44) | 327.2 ± 349.6 (n = 223) | 0.0002 |
| Hemoglobin (g/dL) | 11.9 ± 1.7 | 13.0 ± 1.7 | <0.001 |
| Creatinine (mg/dL) | 1.41 ± 0.71 | 1.15 ± 0.76 | 0.005 |
| Estimated GFR (mL/min/1.73 m2) | 46.6 ± 19.4 | 57.0 ± 24.8 | 0.002 |
| Sodium (mmol/L) | 139.1 ± 3.6 | 139.5 ± 3.1 | NS |
NS = not statistically significant.
Data are mean ± SD, or n.